Track Ajanta Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -1.35 %
Low
3,199.9
High
3,390.1
1 Month returns: -7.76 %
Low
3,199.9
High
3,758.9
1 Year returns: 35.96 %
Low
2,381.5
High
3,796.9
3 Year CAGR: 23.74 %
Low
1,650.1
High
3,796.9
5 Year CAGR: 17.95 %
Low
1,061.8
High
3,796.9
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Ajanta Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Ajanta Pharma Ltd. Shareholding Pattern
Quarterly breakdown of Ajanta Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Ajanta Pharma Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Ajanta Pharma Ltd.?
The current share price of Ajanta Pharma Ltd. is ₹ 3,283.90 as of 23 Oct 2026.
What is the market capitalisation of Ajanta Pharma Ltd.?
The market capitalisation of Ajanta Pharma Ltd. stands at ₹ 41,035.30 Cr.
What is the PE ratio of Ajanta Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd. is 36.16 as of the latest trailing twelve months data.
What is the ROE and ROCE of Ajanta Pharma Ltd.?
Ajanta Pharma Ltd. has a Return on Equity (ROE) of 25.39% and a Return on Capital Employed (ROCE) of 30.76% as per the latest financial reports.
What is the 52-week high and low of Ajanta Pharma Ltd.?
The 52-week high of Ajanta Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Ajanta Pharma Ltd.?
The dividend yield of Ajanta Pharma Ltd. is 0.85% based on the current market price.
What is the FII and DII holding in Ajanta Pharma Ltd.?
Foreign Institutional Investors (FII) hold 7.62%, Domestic Institutional Investors (DII) hold 21.53% and retail/public investors hold 6.78% of Ajanta Pharma Ltd. shares.
What sector does Ajanta Pharma Ltd. belong to?
Ajanta Pharma Ltd. operates in the Healthcare sector. 64.29% of analysts have a Buy or Strong Buy rating on Ajanta Pharma Ltd. with a consensus target price of ₹ 3,800.00, implying 15.72% upside from current levels.
What is the beta of Ajanta Pharma Ltd.?
The beta of Ajanta Pharma Ltd. is 0.49, indicating its price volatility relative to the broader market. Over the past 1 year, Ajanta Pharma Ltd. has delivered an absolute return of 36.30%.
What is the RSI of Ajanta Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Ajanta Pharma Ltd. is 34.95, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Promoter
70.50
70.51
70.51
70.34
70.34
70.34
70.34
70.34
70.48
70.48
70.48
66.11
66.11
66.21
66.21
66.21
66.21
66.27
66.26
66.26
66.26
66.26
66.25
66.25
66.25
63.48
63.47
Indian Promoter
70.50
70.51
70.51
70.34
70.34
70.34
70.34
70.34
70.48
70.48
70.48
66.11
66.11
66.21
66.21
66.21
66.21
66.27
66.26
66.26
66.26
66.26
66.25
66.25
66.25
63.48
63.47
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
20.28
20.00
19.90
20.38
20.99
21.18
21.22
21.54
21.38
21.21
21.36
25.89
25.98
26.00
25.58
25.78
26.03
25.78
26.22
26.29
26.35
26.37
26.44
26.57
26.64
29.48
29.57
Mutual Funds / UTI
9.25
9.51
9.93
9.78
9.53
9.95
10.26
10.74
10.50
10.88
11.14
13.57
13.77
13.07
12.84
13.86
14.76
14.84
14.93
14.89
15.13
14.72
14.67
15.49
15.22
18.10
17.95
FI/Bank/Insurance
0.62
0.84
0.69
1.08
1.35
1.09
1.25
0.81
1.11
1.04
1.01
1.28
1.30
1.64
2.07
2.15
2.16
2.20
1.57
1.48
1.58
2.01
2.64
2.65
2.70
3.29
3.58
Govt
0.74
0.74
0.75
0.76
0.76
0.43
0.43
0.45
0.45
0.45
-
-
-
-
-
-
-
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
-
-
FII
8.91
8.23
7.71
7.90
8.37
8.94
8.72
8.95
8.64
8.30
8.23
10.07
10.00
10.19
9.99
9.11
8.54
8.36
9.11
9.26
8.86
8.86
8.53
7.97
8.26
7.68
7.62
Other Institutions
0.76
0.68
0.80
0.85
0.98
0.78
0.56
0.59
0.67
0.54
0.98
0.97
0.90
1.11
0.69
0.66
0.56
0.37
0.59
0.65
0.77
0.77
0.59
0.44
0.44
0.41
0.41
Non-Institution
9.21
9.49
9.59
9.27
8.67
8.47
8.43
8.12
8.14
8.31
8.15
8.00
7.91
7.79
8.20
8.01
7.76
7.94
7.52
7.45
7.39
7.38
7.32
7.19
7.12
7.03
6.96
Bodies Corporate
0.54
0.41
0.34
0.33
0.33
0.11
0.28
0.25
0.25
0.24
0.24
0.28
0.22
0.25
0.30
0.28
0.24
0.25
0.21
0.19
0.17
0.22
0.18
0.17
0.17
0.17
0.18
Others (incl. Retail)
No. of shareholders
8.67
38,585
9.08
45,635
9.25
48,248
8.94
48,883
8.34
44,280
8.36
45,277
8.15
51,557
7.87
57,081
7.89
59,899
8.07
63,545
7.91
61,132
7.72
58,861
7.69
82,667
7.54
54,008
7.90
55,383
7.73
53,464
7.52
54,648
7.69
69,430
7.31
63,403
7.26
65,936
7.22
69,874
7.16
67,978
7.14
66,926
7.02
64,611
6.95
67,117
6.86
64,452
6.78
61,037
3,283.9013.3 (0.41%)
35.96% in past 1 year
Holdings and Presence
Indices and prominent investors with a stake in this stock.
History of Ajanta Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 32/share
Record date: 5th Aug 2026Ex-date: 5th Aug 2026
Announced on: 20th Jul 2026
Dividend₹ 28/share
Record date: 10th Nov 2025Ex-date: 10th Nov 2025
Announced on: 24th Oct 2025
Dividend₹ 28/share
Record date: 6th Nov 2024Ex-date: 6th Nov 2024
Announced on: 23rd Oct 2024
Others
Ex-date: 30th May 2024Announced on: 2nd May 2024
"On Market Tender offer. As on 27 June 2024 Total shares repurchased 1028881."
Dividend₹ 26/share
Record date: 8th Feb 2024Ex-date: 8th Feb 2024
Announced on: 25th Jan 2024
Company Profile
Overview of Ajanta Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of...
Ajanta House,, Charkop, Kandivli West,, MUMBAI, 400067, India
Stock Analysis
Fundamental analysis overview of Ajanta Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 91.7 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
91.7 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 1.63% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
Consistently pays dividend
The company has not missed dividend payments once in the last 8 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 36.16 indicates that the stock is expensive on a standalone basis and is at a 18.67% premium to industry median P/E
What is P/E Ratio?
Median: 30.47
Value 36.16
-0.82614.73
Low dividend yield
The company has a low dividend yield of 0.85%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 47.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion